Evaluation of the Anti-inflammatory, Phagocytic, and Antioxidant Potential of ORSL® Immunity+ in Lipopolysaccharide-stimulated Human Peripheral Blood Mononuclear Cells.
{"title":"Evaluation of the Anti-inflammatory, Phagocytic, and Antioxidant Potential of ORSL<sup>®</sup> Immunity+ in Lipopolysaccharide-stimulated Human Peripheral Blood Mononuclear Cells.","authors":"Sanjay Kalra, Trupti Gilada, Ashwin Dabhi, Vijay Chamle, Deepanshi Dhar, Tarique Meer, Michael Southall, Ashok Godavarthi, Amol Patil, Harshad Malve, Ashley Barlow","doi":"10.59556/japi.73.1090","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Maintaining optimal hydration and electrolyte balance is essential for immune function, as it supports cellular homeostasis and immune defense mechanisms. Electrolyte-based micronutrient drinks helps replenish essential nutrients, including zinc, selenium, and vitamin E, which play key roles in modulating immune responses, mitigating oxidative stress, and regulating inflammation. Lipopolysaccharide (LPS)-induced inflammation and oxidative stress are major contributors to immune dysfunction, necessitating interventions that enhance immune resilience.</p><p><strong>Objective: </strong>To evaluate the immunomodulatory potential of ORSL® Immunity<sup>+</sup> in mitigating inflammation, enhancing phagocytic activity, and providing antioxidant protection in LPS-stimulated peripheral blood mononuclear cells (PBMCs) Materials and methods: PBMCs were isolated from human blood and stimulated with LPS to induce an inflammatory response. The effects of ORSL® Immunity+ on the immune function of treated cells were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cytotoxicity, enzyme-linked immunosorbent assay (ELISA) for inflammatory markers [tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin 6 (IL-6), interferon gamma (IFN-γ), nitric oxide (NO)], oxygen radical absorbance capacity (ORAC) assay for antioxidant capacity, and phagocytosis assay.</p><p><strong>Results: </strong>ORSL® Immunity+ demonstrated no cytotoxic effects on PBMCs. The treatment significantly reduced the levels of inflammatory markers, indicating an anti-inflammatory effect. Additionally, ORSL<sup>®</sup> Immunity<sup>+</sup> enhanced phagocytic activity in a dose-dependent manner against <i>Escherichia coli,</i> suggesting improved immune response. Antioxidant capacity was also significantly increased, as evidenced by the ORAC assay, highlighting its potential in mitigating oxidative stress.</p><p><strong>Conclusion: </strong>ORSL® Immunity+ exhibits promising immunomodulatory properties by reducing inflammation, enhancing phagocytosis, and improving antioxidant potential in LPS-stimulated PBMCs. These findings support a potential role in immune health alongside improving hydration status, warranting further clinical evaluation.</p>","PeriodicalId":22693,"journal":{"name":"The Journal of the Association of Physicians of India","volume":"73 8S","pages":"21-27"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Association of Physicians of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59556/japi.73.1090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Maintaining optimal hydration and electrolyte balance is essential for immune function, as it supports cellular homeostasis and immune defense mechanisms. Electrolyte-based micronutrient drinks helps replenish essential nutrients, including zinc, selenium, and vitamin E, which play key roles in modulating immune responses, mitigating oxidative stress, and regulating inflammation. Lipopolysaccharide (LPS)-induced inflammation and oxidative stress are major contributors to immune dysfunction, necessitating interventions that enhance immune resilience.
Objective: To evaluate the immunomodulatory potential of ORSL® Immunity+ in mitigating inflammation, enhancing phagocytic activity, and providing antioxidant protection in LPS-stimulated peripheral blood mononuclear cells (PBMCs) Materials and methods: PBMCs were isolated from human blood and stimulated with LPS to induce an inflammatory response. The effects of ORSL® Immunity+ on the immune function of treated cells were assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cytotoxicity, enzyme-linked immunosorbent assay (ELISA) for inflammatory markers [tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin 6 (IL-6), interferon gamma (IFN-γ), nitric oxide (NO)], oxygen radical absorbance capacity (ORAC) assay for antioxidant capacity, and phagocytosis assay.
Results: ORSL® Immunity+ demonstrated no cytotoxic effects on PBMCs. The treatment significantly reduced the levels of inflammatory markers, indicating an anti-inflammatory effect. Additionally, ORSL® Immunity+ enhanced phagocytic activity in a dose-dependent manner against Escherichia coli, suggesting improved immune response. Antioxidant capacity was also significantly increased, as evidenced by the ORAC assay, highlighting its potential in mitigating oxidative stress.
Conclusion: ORSL® Immunity+ exhibits promising immunomodulatory properties by reducing inflammation, enhancing phagocytosis, and improving antioxidant potential in LPS-stimulated PBMCs. These findings support a potential role in immune health alongside improving hydration status, warranting further clinical evaluation.